To assess SLAMF8 levels in PCa and examine its association with immune cell infiltration, we employed immunohistochemistry to measure the levels of SLAMF8, PD1, CD3, and CD19 in both PCa and benign prostatic hyperplasia (BPH) samples. This evidence concerns the gene CD19 and benign prostatic hyperplasia.